捷強裝備(300875.SZ):擬在四川綿陽建立核化生安全裝備軍民兩用製造中心
格隆匯9月30日丨捷強裝備(300875.SZ)公佈,為進一步完善公司“平戰一體的核化生安全裝備全產業鏈”戰略佈局,更好地進行市場開發和業務拓展,充分藉助川渝地區的區位優勢和市場資源優勢深入挖掘項目、吸引人才、拓展市場,培育新的利潤增長點。為提高核化生安全裝備及大科學裝備配套的技術研發和生產能力,公司擬在四川省綿陽市建立核化生安全裝備軍民兩用製造中心,項目總投資不超過5億元。此次投資建設項目將根據實際進展分期投入,最終項目開支以實際投資金額為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.